Précédent|Prochain

Relations entre la pneumonie aiguë et les voies de signalisation, progrès de la régulation par la médecine chinoise

  • role： First author第一作者
  • Affiliation：

    School of Clinical Medicine， Chengdu University of Traditional Chinese Medicine （TCM）， Chengdu 610032， China

  • Email：1121174213@qq.com
  • Introduction：罗成，在读博士，从事中医药防治呼吸病与老年病的临床研究，E-mail：1121174213@qq.com
LUO Cheng1,  
  • Affiliation：

    Innovation Research Institute/Interdisciplinary Research Institute， Chengdu University of TCM， Chengdu 610093， China

NING Bo2,  
  • Affiliation：

    School of Clinical Medicine， Chengdu University of Traditional Chinese Medicine （TCM）， Chengdu 610032， China

ZHANG Xinyue1,  
  • Affiliation：

    School of Clinical Medicine， Chengdu University of Traditional Chinese Medicine （TCM）， Chengdu 610032， China

HUO Yuzhi1,  
  • Affiliation：

    School of Clinical Medicine， Chengdu University of Traditional Chinese Medicine （TCM）， Chengdu 610032， China

WU Xinhui1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Pengzhou Third People's Hospital， Pengzhou 611931， China

  • Email：421492693@qq.com
  • Introduction：叶远航，硕士，住院医师，从事中医药防治呼吸系统疾病的临床研究，E-mail：421492693@qq.com；
YE Yuanhang3*,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Clinical Medicine， Chengdu University of Traditional Chinese Medicine （TCM）， Chengdu 610032， China

    Affiliated Hospital of Chengdu University of TCM， Chengdu 610072， China

  • Email：wangfei896@163.com
  • Introduction：王飞，博士，主任医师，博士生导师，从事中医药防治呼吸病与老年病的临床研究，E-mail：wangfei896@163.com
WANG Fei14*

résumé

La pneumonie aiguë est l'une des affections respiratoires aiguës critiques les plus courantes en clinique, caractérisée par une progression rapide, une difficulté de traitement, un taux de létalité élevé, de nombreuses complications et d'autres caractéristiques, constituant une grave menace pour la santé et la vie des patients. Le mécanisme de survenue de la pneumonie aiguë est extrêmement complexe et des études ont montré un lien étroit entre le développement de la pneumonie aiguë et plusieurs voies de signalisation. Actuellement, le traitement de la pneumonie aiguë repose principalement sur l'antibiothérapie, la ventilation mécanique et les corticostéroïdes, et les résultats cliniques sont souvent insatisfaisants. Par conséquent, la recherche de méthodes de traitement alternatives sûres et efficaces revêt une importance particulière. Ces dernières années, avec l'avancée des études de médecine chinoise, la médecine chinoise et la thérapie traditionnelle chinoise ont suscité un grand intérêt dans le traitement de la pneumonie aiguë. Par conséquent, cet article examine la relation entre la pneumonie aiguë et les voies de signalisation correspondantes au cours des dernières années et comment la médecine chinoise régule ces voies de signalisation pour traiter la pneumonie aiguë. Il a été constaté que la médecine chinoise pouvait réduire la réaction inflammatoire, inhiber l'apoptose et la nécrose cellulaire, améliorer le stress oxydatif et d'autres effets du traitement de la pneumonie aiguë. L'auteur a constaté que chaque voie de signalisation régule la pneumonie aiguë de manière différente, donc la réduction de la réaction inflammatoire est le mécanisme d'action principal de la médecine chinoise dans le traitement de la pneumonie aiguë.

mots-clés

pneumonie aiguë; voies de signalisation; médecine chinoise; progrès de la recherche

References

  1. 1.
    LUO C，YE Y H，SHENG G G，et al.Research progress on pneumonia-related signaling pathways and traditional Chinese medicine treatment［J］.World Chin Med，2023，18（12）：1778-1783.
  2. 2.
    LUO C，YE Y H，SHENG G G，et al.Research progress in the treatment of severe pneumonia by traditional Chinese medicine［J］.J Emerg Syndromes Tradit Chin Med，2023，32（5）：929-932.
  3. 3.
    NAIR G B，NIEDERMAN M S.Updates on community acquired pneumonia management in the ICU［J］.Pharmacol Ther，2021，217：107663.
  4. 4.
    LUO C，YE Y H，ZHENG L，et al.Research progress of traditional Chinese medicine based on "lung-intestinal" axis regulating intestinal flora in the treatment of severe pneumonia［J］.Chin Med Rep，2023，20（6）：33-36.
  5. 5.
    YE Y H，LUO C，KE J，et al.Effect of Maxingshigan decoction combined with Qianjin Weijian decoction in the treatment of severe pneumonia complicated with respiratory failure and its influence on inflammatory factors［J］.Lishizhen Med Mater Med Res，2023，34（5）：1150-1152.
  6. 6.
    FERRER M，TRAVIERSO C，CILLONIZ C，et al.Severe community-acquired pneumonia：Characteristics and prognostic factors in ventilated and non-ventilated patients［J］.PLoS One，2018，13（1）：e191721.
  7. 7.
    NIEDERMAN M S，TORRES A.Severe community-acquired pneumonia［J］.Eur Respir Rev，2022，31（166）：220123.
  8. 8.
    MARTIN-LOECHES I，TORRES A，NAGAVCI B，et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia［J］.Intensive Care Med，2023，49（6）：615-632.
  9. 9.
    MARTIN-LOECHES I，GARDUNO A，POVOA P，et al. Choosing antibiotic therapy for severe community-acquired pneumonia［J］.Curr Opin Infect Dis， 2022，35（2）：133-139.
  10. 10.
    BLOT M，BOUR J B，QUENOT J P，et al. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome［J］.J Transl Med，2020，18（1）：457.
  11. 11.
    ZHANG Z，DOU H，TU P，et al. Serum cytokine profiling reveals different immune response patterns during general and severe Mycoplasma pneumoniae pneumonia［J］.Front Immunol，2022，13：1088725.
  12. 12.
    LUO C，YE Y H，SHENG G G，et al.Research progress of Xuanbai Chengqi decoction and its additive prescription in the treatment of respiratory diseases［J］.Chin Tradit Pat Med，2023，45（10）：3369-3375.
  13. 13.
    JI L Y，WU Q L，CHEN Z T，et al.Effect of Scutellariae Radix-Coptidis Rhizoma on stabilization of atherosclerotic vulnerable plaques via inhibition of TLR4/MyD88/NF-κB signaling pathway［J］.Chin J Exp Tradit Med Form，2024，30（13）：28-36.
  14. 14.
    WANG Y J，LI H，SHI Y S.Expression of concern：miR-143-3p impacts on pulmonary inflammatory factors and cell apoptosis in mice with mycoplasmal pneumonia by regulating TLR4/MyD88/NF-κB pathway［J］.Biosci Rep，2021，41（4）：BSR-20193419_EOC.
  15. 15.
    HIRANO T，HIRAYAMA D，WAGATSUMA K，et al. Immunological mechanisms in inflammation-associated colon carcinogenesis［J］.Int J Mol Sci，2020，21（9）：3062.
  16. 16.
    YAN H，WANG L Y，WU X L，et al.Efficacy of prednisone combined with azithromycin sequential therapy in treatment of severe Mycoplasma pneumoniae pneumonia in children and its effects on serum TLR4/MyD88/NF-κB signaling pathway related proteins and downstream inflammatory factors［J］.Chin J Clin New Chin Med，2023，16（5）：474-478.
  17. 17.
    MO W L，WU S Q，LI Y H，et al.Effects of Xiyanping injection combined with oseltamivir on TLR4/NF-κB signaling pathway and downstream inflammatory factors in patients with acute severe viral pneumonia［J］.Chin J Nosocomiol，2022，32（19）：2891-2895.
  18. 18.
    SUN Z X，SUO H L，LI H，et al.Mechanism of ginsenoside Rg1 regulating TLR4/NF-κB signaling pathway against myocardial tissue injury in rats with severe pneumonia［J］.Tianjin Med J，2021，49（3）：271-276.
  19. 19.
    LIU J X，LI X，YAN F G，et al. Protective effect of forsythoside B against lipopolysaccharide-induced acute lung injury by attenuating the TLR4/NF-κB pathway［J］.Int Immunopharmacol，2019，66：336-346.
  20. 20.
    LIU T Y，ZHAO L L，CHEN S B，et al. Polygonatum sibiricum polysaccharides prevent LPS-induced acute lung injury by inhibiting inflammation via the TLR4/MyD88/NF-kappaB pathway［J］.Exp Ther Med，2020，20（4）：3733-3739.
  21. 21.
    WANG H，LI X L，ZHANG Q J.Effects of salidroside on pulmonary inflammation and NF-κB， p38 signal in rats with severe pneumonia［J］.J Microcirc，2021，31（3）：7-12.
  22. 22.
    ZHANG Z L，LIU P J，CHEN J，et al.Morin ameliorates lung injury in rats with severe pneumonia by inhibiting HMGB1/TLR4/NF-κB pathway［J］.Immunol J，2022，38（6）：478-486.
  23. 23.
    ZHANG C，WANG X，WANG C，et al. Qingwenzhike prescription alleviates acute lung injury induced by LPS via inhibiting TLR4/NF-κB pathway and NLRP3 inflammasome activation［J］.Front Pharmacol，2021，12：790072.
  24. 24.
    YU D X.Qinghua prescription affects the state of illness related indicators in patients with severe pneumonia and inflammatory mechanism exploring［D］.Beijing：China Academy of Chinese Medical Sciences，2016.
  25. 25.
    TANG Y M.Experimental study on pulmonary epithelial mesenchymal transformation of SMPP mice by supplementing Yangyin Qingfei decoction［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2021.
  26. 26.
    LI T S，XI Z W，DONG W J，et al.Curcumin induces cycle arrest of colon cancer HCT116 cells via JAK1/STAT1/p21 pathway［J］.Chin J Exp Tradit Med Form，2024，30（9）：74-82.
  27. 27.
    TALOTTA R. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease［J］.Immunotherapy-Uk，2021，13（3）：241-256.
  28. 28.
    HU W，ZHANG T，SHENG S C，et al.Mechanism of IGF-1R on sepsis rats by regulating JAK/STAT signaling pathway［J］.J Mod Lab Med，2022，37（2）：6-11.
  29. 29.
    WEI F，WANG X Y，LIU Z Y.Effect of Xuebijing on lung tissue damage induced by Klebsiella pneumoniae in rats with severe pneumonia through miR-155/JAK2/STAT1 signaling pathway［J］.J Pract Intern Med，2023，39（18）：2335-2341.
  30. 30.
    XUE H，LI M. Protective effect of pterostilbene on sepsis-induced acute lung injury in a rat model via the JAK2/STAT3 pathway［J］.AMT，2020，8（21）：1452.
  31. 31.
    WU P，HE W L，FU Y，et al.Effects of Fraxin on inflammatory factors expression and related pathways activation of rats with severe pneumonia［J］.Immunol J，2020，36（4）：292-298.
  32. 32.
    SUN Y，SHI Z B，LIU M X，et al.Effects of yam polysaccharide on myocardial injury and JAK2/STAT3 signal pathway in septic rats［J］.Chin J Arterioscler，2022，30（8）：669-675.
  33. 33.
    HU J，ZHOU Y L，LIU K.Effect of hesperidin on inflammation and apoptosis of lung tissue in rats with severe pneumonia［J］.Chin J Immunol，2023，39（4）：727-732.
  34. 34.
    WANG G Q，LI S，YU L Z，et al.Explore the mechanism of prevention of Qingwen Baidu Yin via JAK2/STAT3 and IKKα/NF-κB signal transduction pathway in sepsis rat［J］.Pharmacol Clin Chin Mater Med，2018，34（3）：2-5.
  35. 35.
    WEI F，WANG X Y，LIU Z Y.Effect of Xuebijing on lung tissue damage induced by Klebsiella pneumoniae in rats with severe pneumonia through miR-155/JAK2/STAT1 signaling pathway［J］.J Pract Med，2023，39（18）：2335-2341.
  36. 36.
    LUO C，YE Y H，KE J.Research progress in the treatment of pulmonary fibrosis using traditional Chinese medicine based on the PI3K/AKT signaling pathway［J］.J Shenyang Pharm Univ，2024，doi：.
  37. 37.
    FATTAHI S，KHALIFEHZADEH-ESFAHANI Z，MOHAMMAD-REZAEI M，et al. PI3K/Akt/mTOR pathway：A potential target for anti-SARS-CoV-2 therapy［J］.Immunol Res，2022，70（3）：269-275.
  38. 38.
    SUN Y L，ZHANG D M，HU F，et al.Effects of Candida colonization in respiratory tract on severe bacterial ventilator-associated pneumonia and PI3K/Akt/NF-κB signaling pathway［J］.Chin J Nosocomiol，2023，33（7）：1006-1010.
  39. 39.
    JIANG Y，ZHANG L Y，HUANG W.Effects of miR-149-5p overexpression on the PI3K/Akt/mTOR pathway in the lung tissue of rats with severe pneumonia［J］.Hebei Med J，2022，44（2）：180-183.
  40. 40.
    LIU W Q.Protective effect of curcumin on myocardium injury in rats with severe pneumonia and regulation mechanism of signal pathway［J］.Chin J Gerontol，2024，44（2）：463-466.
  41. 41.
    WEI F，WANG X Y，LIU Z Y.Effect and mechanism of aesculin on lung injury and fibrosis in rats with severe pneumonia induced by klebsiella pneumoniae［J］.Chin Arch Tradit Chin Med，2023，41（1）：197-200.
  42. 42.
    ZHANG T，ZHAO X，ZHANG X，et al. Research on the metabolic regulation mechanism of Yangyin Qingfei decoction plus in severe pneumonia caused by Mycoplasma pneumoniae in mice［J］.Front Pharmacol，2024，15：1376812.
  43. 43.
    WANG S H，LI C X，WANG Z W.Mechanism of Xuanbai Chengqi decoction in the treatment of severe COVID-19 case based on network pharmacology and literature screening［J］.World Sci Technol Mod Tradit Chin Med，2020，22（10）：3472-3484.
  44. 44.
    LUO C，YE Y H，JIANG C，et al.Mechanism of Xuanbai Chengqi Decoction in treating acute lung injury based on network pharmacology and experimental verification［J］.China J Chin Mater Med，2024，49（16）：4329-4337.
  45. 45.
    WU G Q，CHEN Y，JIANG J.An experimental study of effect of Wenshen Yiqi medicine on expression of MMP-2 and MMP-9 in rats with severe pneumonia［J］.Chin J Gen Pract，2016，14（7）：1073-1076.
  46. 46.
    MAO W，WU H H，WANG Y，et al.Therapeutic effects of Xiao Xumingtang combined with electroacupuncture on cerebral ischemia/reperfusion injury via NLRP3/GSDMD/Caspase-1 pathway［J］.Chin J Exp Tradit Med Form，2024，30（19）：39-47.
  47. 47.
    FU J，WU H. Structural mechanisms of NLRP3 inflammasome assembly and activation［J］.Annu Rev Immunol，2023，41：301-316.
  48. 48.
    ZHANG D X，WU K L，FU C，et al.Detection and clinical significance of serum s CD163，NLRP3，and IL-37 in children with severe pneumonia caused by Mycoplasma pneumoniae pneumonia［J］.Hainan Med，2024，35（9）：1307-1311.
  49. 49.
    LYV G F，LIAN L Y，LYV W L，et al.Association between severe Mycoplasma pneumoniae pneumonia in children and NLRP3 inflammasome pathway［J］.Chin J Nosocomiol，2024，34（2）：258-262.
  50. 50.
    LU J，YUAN M，FENG X H，et al.Protective effect of resveratrol on ROS/NLRP3/Caspase-1 pathway-mediated pyroptosis on lung injury in rats with severe pneumonia［J］.J Mol Diagn Ther，2023，15（5）：888-891.
  51. 51.
    WANG Y J，ZHANG J，SONG W W，et al.Emodin reduces lung damage in rats with severe pneumonia by regulating ROS/TXNIP/NLRP3-mediated pyroptosis pathway［J］.Chin J Pathophysiol，2021，37（7）：1240-1245.
  52. 52.
    ZHANG Y F，FANG W.Effects of Maxing Shigan decoction combined with Tigecycline in treatment of elderly patients with severe pneumonia caused by multidrug-resistant bacteria［J］.Med J Chin People Health，2023，35（24）：96-98.
  53. 53.
    LIU H.Study on the clinical effect and mechanism of Feire Kechuan decoction on patients with severe pneumonia syndrome of phlegm-heat obstructing lung［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2023.
  54. 54.
    LIANG Y J.The inhibition effect of NLRP3 inflammatory vesicles bythe formula for Qingrejiedu Huatan the inflammatory response of rats in a severe pneumonia model［D］.Zhengzhou：Henan University of Traditional Chinese Medicine，2022.
  55. 55.
    WANG G T.Experimental study on the effect of Yangyin Qingfei decoction on SMPP mice based on ROS/NLRP3［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2020.
  56. 56.
    SIVINSKI J，ZHANG D D，CHAPMAN E. Targeting Nrf2 to treat cancer［J］.Semin Cancer Biol，2021，76：61-73.
  57. 57.
    SCHMIDLIN C J，SHAKYA A，DODSON M，et al. The intricacies of Nrf2 regulation in cancer［J］.Semin Cancer Biol，2021，76：110-119.
  58. 58.
    WANG S X，ZHANG L，JIN N N，et al.Relationship between virulence factors in clinical isolates and expressions of key autophagy proteins in PBMCs of elderly patients with severe Klebsiella pneumoniae infection［J］.Chin J Nosocomiol，2023，33（9）：1289-1293.
  59. 59.
    WANG Y，LI H，XIE Y.Effects of salidroside on Nrf2/Keap1 pathway and airway inflammation in rats with bronchopneumonia［J］.Drug Chin，2022，37（10）：2184-2189.
  60. 60.
    ZHANG X，LI W H.Study on effect of lncRNA H19 on lung tissue of mice with mycoplasma infection pneumonia based on Nrf2/HO-1 signal pathway［J］.Chin J Immunol，2022，38（14）：1689-1695.
  61. 61.
    WANG Y B，JIAO B，WANG X Q，et al.Effect of schisandrin B on NRF2/Keap1/PGC-1α signaling pathway in lung tissue of rats with severe pneumonia caused by Klebsiella［J］.China Trop Med，2023，23（12）：1313-1317.
  62. 62.
    SU Y Q.Study on the regulatory mechanism of Yangyin Qingfei Decoction on oxidative damage in SMPP mice［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2023.
  63. 63.
    VAZQUEZ G M，KOLLEF M H. Next steps in pneumonia severity scores［J］.Clin Infect Dis，2021，72（6）：950-952.
  64. 64.
    FLORIN T A，AMBROGGIO L，BROKAMP C， et al. Proadrenomedullin predicts severe disease in children with suspected community-acquired pneumonia［J］.Clin Infect Dis，2021，73（3）：e524-e530.
  65. 65.
    LI J，LUU L，WANG X，et al. Metabolomic analysis reveals potential biomarkers and the underlying pathogenesis involved in Mycoplasma pneumoniae pneumonia［J］.Emerg Microbes Infect，2022，11（1）：593-605.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website